• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biomea Fusion, Inc. - Common Stock (NQ:BMEA)

1.370 +0.050 (+3.79%)
Delayed Quote Updated: 4:00 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,688,987
Open 1.320
Bid (Size) 1.360 (100)
Ask (Size) 1.380 (2,100)
Prev. Close 1.320
Today's Range 1.300 - 1.380
52wk Range 0.8719 - 2.237
Shares Outstanding 35,631,576
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Diabetes Cell Therapy Enters a New Era as Billion-Dollar Market Opportunity Takes Shape
October 07, 2026
From Insulin Management To Cell Replacement: The Diabetes Revolution Is Accelerating New York, NY – October 7, 2026 – Diabetes cell therapy is moving into a very different phase. For years, the idea of... 
Via FinancialNewsMedia
News headline image
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
September 23, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire

Performance

52-Week Range 38.8% below 52-week high
1.370
0.8752W Low 2.2452W High
1 Week
1.221W Low 1.361W High

Biomea Fusion, Inc. - Common Stock (BMEA) traded between $0.87 and $2.24 over the past 52 weeks and last traded at $1.37, 38.8% below its 52-week high. Over the past week it ranged between $1.22 and $1.36.

Past 12 Months
+5.4%
-29.0%
+5.4%
-22.2%
+2.2%
-25.7%
1W +$0.07
1M -$0.56
3M +$0.07
6M -$0.39
YTD +$0.03
1Y -$0.47

BMEA was -25.7% over the past year, -22.2% over six months, +2.2% year to date, +5.4% in the last week.

12 Months vs Market
BMEA
-25.7%
DIA
+9.8%
SPY
+15.7%
QQQ
+23.7%
IWM
+13.7%

Over the past 12 months BMEA returned -25.7% versus DIA (Dow) +9.8%, SPY (S&P 500) +15.7%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 1.15× 3-mo avg
Today 1,688,987 3-mo avg 1.5M
1W
918.2K
1M
2.0M
3M
1.5M
6M
1.4M
YTD
1.4M
1Y
1.5M

BMEA most recently traded 1,688,987 shares against a 3-month average daily volume of 1.5M.

More News

Read More
These stocks are moving in today's after hours session ↗
September 22, 2026
Via Chartmill
News headline image
Biomea Fusion Announces Proposed Public Offering of Securities
September 22, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Inc (NASDAQ:BMEA) Q1 2026 Earnings Beat and Pipeline Progress Drive Cautious Optimism ↗
May 11, 2026
Via Chartmill
Topics Earnings
News headline image
Biomea Fusion to Participate in Upcoming Investor Conferences
September 03, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
Monday's session: gap up and gap down stocks ↗
August 24, 2026
Via Chartmill
News headline image
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
August 24, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
August 13, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
August 05, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
June 05, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
June 03, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
May 11, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
May 05, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
April 27, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
March 31, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
March 24, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib ↗
March 14, 2026
Via Benzinga
News headline image
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
March 14, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Participate at Upcoming Investor Conferences
February 19, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
January 12, 2026
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
December 09, 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
December 05, 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
News headline image
Which stocks are moving after the closing bell on Tuesday? ↗
December 02, 2025
Via Chartmill

Frequently Asked Questions

Is Biomea Fusion, Inc. - Common Stock publicly traded?
Yes, Biomea Fusion, Inc. - Common Stock is publicly traded.
What exchange does Biomea Fusion, Inc. - Common Stock trade on?
Biomea Fusion, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Biomea Fusion, Inc. - Common Stock?
The ticker symbol for Biomea Fusion, Inc. - Common Stock is BMEA on the Nasdaq Stock Market
What is the current price of Biomea Fusion, Inc. - Common Stock?
The current price of Biomea Fusion, Inc. - Common Stock is 1.370
When was Biomea Fusion, Inc. - Common Stock last traded?
The last trade of Biomea Fusion, Inc. - Common Stock was at 10/08/26 04:00 PM ET
What is the market capitalization of Biomea Fusion, Inc. - Common Stock?
The market capitalization of Biomea Fusion, Inc. - Common Stock is 48.82M
How many shares of Biomea Fusion, Inc. - Common Stock are outstanding?
Biomea Fusion, Inc. - Common Stock has 49M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap